ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "B cells"

  • 2018 American Transplant Congress

    Achieving Allograft Tolerance through Antigen-Specific Regulatory B Cells

    C. Rickert,1,2 S. Kimura,1,2 L. Kojima,1 K. Lee,1 M. Aburawi,1 F. Fontan,1 K. Deng,1 H. Yeh,1,2 J. Markmann.1,2

    1Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA; 2Transplantation Unit, Department of Surgery, Massachusetts General Hospital, Boston, MA.

    IntroductionA complete understanding of the role of antigen-specificity in the development of B cell mediated allograft tolerance has remained elusive. Previous work in our lab…
  • 2018 American Transplant Congress

    Accommodation and Antibody Mediated Rejection Are Associated with Distinct TACI Polymorphisms in Kidney Transplant Recipients

    M. Cascalho, M. Barbosa,1 E. Farkash,2 J. Platt.1

    1Surgery, University of Michigan, Ann Arbor, MI; 2Pathology, University of Michigan, Ann Arbor, MI.

    A. Trans-membrane Activator and CAML Interactor (TACI) gene is among the 5% most polymorphic genes in humans, TACI controls B cell differentiation and memory and…
  • 2018 American Transplant Congress

    Designing Novel Selective Immunoproteasome Inhibitors Reveals a Critical Role of the Immunoproteasome in Protecting Antibody Secreting B Cells from Apoptosis

    J. Assaker,1 N. Murakami,1 S. Eskandari,1 M. Uehara,1 C. Nathan,2 H. Li,3 G. Lin,2 J. Azzi.1

    1Transplantation Renal Center, Harvard Medical School, Boston; 2Microbiology and Immunology, Weill Cornell Medicine, New York; 3Cryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids.

    Constitutive proteasomes (c-20S) are ubiquitously-expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Its inhibitor, bortezomib, is a plasma cell-targeted therapy used in…
  • 2018 American Transplant Congress

    Alloreactive B Cells Acquire Cell-Intrinsic Hyporesponsiveness in Tolerant Recipients

    S. Khiew,1 D. Jain,1 J. Young,1 J. Chen,1 J. Yang,1 Q. Wang,1 D. Yin,1 R. Sciammas,2 A. Chong.1

    1Department of Surgery, The University of Chicago, Chicago, IL; 2Comparative Medicine, University of California, Davis, CA.

    Donor-specific transplantation tolerance has long been an aspiration of clinical transplantation. Recently, we have reported that multiple mechanisms are required to reinforce profound hyporesponsiveness of…
  • 2018 American Transplant Congress

    The Regulatory Role of Plasma Cells (as Bregs) is Counterbalanced by a NOVEL Inflammatory Role in Murine Transplant and Autoimmune Models

    Z. Song,1,2 Y. Zhou,2 Q. Ding,1 D. Rothstein.1

    1Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh; 2School of Medicine, Tsinghua University, Beijing, China.

    Plasma Cells (PCs; B220lowCD138hiBlimp1+Ig+) in LN and spleen were shown to be the major source of B cell lineage IL-10, and absence of PCs worsens…
  • 2018 American Transplant Congress

    Preemptive B Cell Depletion Modulates Pathogenic Alloimmunity Associated with Selective Non-Activating CD28 Blockade

    N. O'Neill,1 T. Zhang,1 W. Sun,1 G. Braileanu,1 X. Cheng,1 I. Tatarov,1 W. Hassanein,1 Z. Habibabady,1 B. Cerel,1 K. Reimann,2 A. Azimzadeh,1 R. Pierson.1

    1Surgery, University of Maryland School of Medicine, Baltimore, MD; 2University of Massachusetts Medical School, Boston, MA.

    Purpose: Because anti-donor alloantibody (alloAb) elaboration is associated with chronic allograft rejection, peri-transplant B cell depletion is being explored to modulate pathogenic alloimmunity. Here, we…
  • 2018 American Transplant Congress

    The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients

    J. Lee,1 J. Park,2 Y. Jung,1 D. Kim,1 J. Lee,1 S. Song,3 J. Lee,4 J. Lee,1 B. Kim,5 M. Kim,1 S. Kim,1 Y. Kim,1 K. Huh.1

    1Surgery, Yonsei University College of Medicine, Seoul, Korea; 2Internal Medicine (Gastroenterology), Yonsei University College of Medicine, Seoul, Korea; 3Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; 4Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; 5Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.

    Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…
  • 2018 American Transplant Congress

    CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation

    B. Nashan,1 H. Tedesco,1 M. van den Hoogen,1 S. Berger,1 D. Cibrik,1 S. Mulgaonkar,1 D. Leeser,1 R. Alloway,1 A. Patel,1 J. Pratschke,1 C. Sommerer,1 A. Wiseman,1 A. van Zuilen,1 U. Laessing,2 J. Rush,2 B. Haraldsson,2 O. Witzke.1

    1CFZ533 Study Group, Basel, Switzerland; 2Novartis Pharma, Basel, Switzerland.

    Purpose: To assess the potential of CFZ533 as primary immunosuppressant in a calcineurin(CNI)-free regimen in de novo kidney transplant (KTx) patients(pts).Method: CFZ533 is a new,…
  • 2018 American Transplant Congress

    Immunomodulation of Alloantibody Responses

    C. Schuetz, M. Climov, A. Paril, Z. Wang, A. Andrews Roy, N. Navarro Alvarez, A. Matar, D. Sachs, R. Duran-Struuck, C. Huang.

    Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.

    We have shown that i.v. exposure to MHC-mismatched donor PBMC using a novel, mild conditioning protocol results in B-cell tolerance with transient T-cell unresponsiveness. Here…
  • 2018 American Transplant Congress

    CD8-Expressing Transitional B Cells Dominate B Cell Reconstitution in Transplanted Monkeys Receiving Mixed Chimerism Conditioning

    K. Pruner, J. Paster, S. Wiebke, O. Jane, H. Isabel, D. Abbas, B. Gilles, M. Joren.

    Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.

    IntroductionTolerance of heart or lung allografts have been achieved for the first time in nonhuman primates (NHPs) using a mixed chimerism conditioning regimen. However, the…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 35
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences